Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: March 27, 2025
Principal Executive Office: Marseille, France
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated March 27, 2025. The document serves to update U.S. investors and incorporates the content into the company's registration statements on Form F-3 and Form S-8.
Key Financial Metrics
The provided filing text does not contain specific financial data. It is a cover document referencing a press release but does not include the text of that release or any financial tables. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
The filing text does not provide details on material changes versus prior periods. The specific content of the press release referenced in Exhibit 99.1 is not included in the input provided.
Guidance, Outlook, and Risks
Management Commentary: The filing explicitly excludes a quotation from Jonathan Dickinson, Chairman of the Executive Board and CEO, as well as references to a live webcast and related links.
Guidance and Risks: No specific guidance, outlook, risks, contingencies, or unusual items are detailed in the provided text.
Investor Verification Checklist
- Review the full text of Exhibit 99.1 (Press Release dated March 27, 2025) to obtain the actual news, financial updates, or operational milestones announced.
- Verify the content of the excluded CEO quotation and webcast details mentioned in the incorporation by reference section.
- Check the company's Form 20-F for the most recent audited financial statements, as this 6-K does not contain financial data.